Avacta Group (AVCT)
AVCT Share PerformanceMore
|52 week high||98.00 26/05/17|
|52 week low||60.00 31/03/17|
|52 week change||-19.50 (-21.91%)|
|4 week volume||1,022,487 23/09/17|
Media for (AVCT)
Latest News« previous» nextMore
19/10/2017 - 07:00 RNS
RNS Number: 9378T Avacta Group PLC 19 October 2017 19 October 2017 Avacta Group plc ("Avacta" or "the Company") Private Shareholder Update Event Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, will be hosting a Private Shareholder event on Wednesday, 15 November 2017 at 2.00 pm until 4.00 pm at finnCap's offices...
16/10/2017 - 10:42 RNS
RNS Number: 6904T Avacta Group PLC 16 October 2017 Hardman Res.: R&D accelerated to advance assets R&D accelerated to advance assets - Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which domin...
12/10/2017 - 07:47 StockMarketWire
Avacta Group chief executive Alastair Smith will be presenting at the Shares Spotlight Evening on 19 Oct at the Novotel Ho...
12/10/2017 - 07:00 RNS
RNS Number: 3574T Avacta Group PLC 12 October 2017 12 October 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta to Present at Shares Spotlight Evening in London Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, is pleased to announce that its Chief Executive Officer, Alastair Smith, wil...
10/10/2017 - 09:55 StockMarketWire
Looking for new investment ideas and want to meet senior directors of listed UK companies? Come along and join Shares ...
10/10/2017 - 08:00 StockMarketWire
Avacta chief technology officer, Dr Matt Johnson is presenting at the Annual Biomarkers & Precision Medicine Congress ...
10/10/2017 - 07:00 RNS
RNS Number: 1238T Avacta Group PLC 10 October 2017 10 October 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta to Present Customer Data at Major US Conference Avacta's Chief Technology Officer will showcase a range of new applications including data generated in collaboration with Covance Avacta Group plc (AIM: AVCT), the ...
09/10/2017 - 16:02 RNS
RNS Number: 1108T Avacta Group PLC 09 October 2017 09 October 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Director Dealing and Issue of Equity Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that application has been made for 5,311 new ordinary shares of 10p each (the "New...
|Dividend yield||0 %|
Latest discussion posts More
“elevator pitch today http://www.youtube.com/watch?v=yuLOFF54y_0 run by proactive investors apparently - never heard of it ...”▼
“Yorkshire Post this afternoon http://www.yorkshirepost.co.uk/news/avacta-is-excited-about-future-progress-1-8787759 mol”▼
“Interview http://www.proactiveinvestors.co.uk/companies/stocktube/8186/avacta-boss-alastair-smith-anticipating-2018-to-be-a-very-significant-year-8186.html http://www.pro ...”▼
Codes & Symbols
|Symbols||AVCT, LSE:AVCT, AVCT.L, AVCT:LN, LON:AVCT, XLON:AVCT|